TD Private Client Wealth’s RxSight RXST Stock Holding History

TD Private Client Wealth’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-92	Closed	-$959	–	1724
2025 Q4	$959	Buy	+92	New	+$923	﹤0.01%	1368

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

TD Private Client Wealth's RXST Position: Q1 2026 in Review

TD Private Client Wealth sold out of RxSight (RXST) in Q1 2026, closing a stake of 92 shares — an estimated $959 sold.

TD Private Client Wealth first reported a position in RXST in Q4 2025 and held it in 1 quarter. The position peaked at $959 in Q4 2025. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

TD Private Client Wealth reported no remaining RxSight position as of Q1 2026 after selling out during the quarter.
TD Private Client Wealth sold 92 RxSight shares in Q1 2026, an estimated $959.
TD Private Client Wealth first reported a position in RxSight in Q4 2025 and held it in 1 quarter.
TD Private Client Wealth's RxSight position peaked at $959 in Q4 2025.
164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.